Journal of Medical Oncology and Therapeutics

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +441518081136

Short Communication - Journal of Medical Oncology and Therapeutics (2025) Volume 10, Issue 1

Adjuvant Therapy in Cancer: Improving Survival and Reducing Recurrence

Guillaume Miller *

Department of Medicine, University Health Network, Canada

*Corresponding Author:
Guillaume Miller
Department of Medicine, University Health Network, Canada
E-mail: guillaume.miller@mail.utoronto.ca

Received: 1-Jan-2025, Manuscript No. JMOT-25-157407; Editor assigned: 3-Jan-2025, PreQC No. JMOT-25-157407 (PQ) Reviewed:17-Jan-2025, QC No. JMOT-25-157407Revised:24-Jan-2025, Manuscript No. JMOT-25-157407; Published:31-Jan-2025, DOI: 10.35841/jmot- 10.1.244

Citation: Miller A. Adjuvant therapy in cancer: Improving survival and reducing recurrence. J Med Oncl Ther. 2025;10(1):244

Visit for more related articles at Journal of Medical Oncology and Therapeutics

Introduction

Adjuvant therapy has emerged as a cornerstone in the multidisciplinary approach to cancer treatment, aiming to improve survival outcomes and reduce the risk of cancer recurrence following primary treatment, typically surgery. This therapeutic strategy involves additional treatment modalities such as chemotherapy, radiotherapy, hormonal therapy, targeted therapy, or immunotherapy administered after the initial surgical intervention. The goal is to eradicate residual microscopic disease that may not be detectable through imaging or pathology but can lead to disease relapse [1].

One of the primary benefits of adjuvant therapy is its potential to improve overall survival and disease-free survival rates. Numerous clinical trials have demonstrated that adjuvant chemotherapy and radiotherapy significantly reduce the risk of recurrence in cancers such as breast cancer, colorectal cancer, and non-small cell lung cancer. For example, in breast cancer, adjuvant hormonal therapies such as tamoxifen and aromatase inhibitors have shown substantial efficacy in hormone receptor-positive tumors [2].

The decision to administer adjuvant therapy is based on several factors, including tumor stage, histological type, receptor status, and patient-specific considerations such as age, overall health, and comorbidities. Biomarkers and genetic testing, including HER2 status in breast cancer and KRAS mutations in colorectal cancer, are increasingly guiding adjuvant therapy decisions to tailor treatment plans to individual patients [3].

Despite its benefits, adjuvant therapy is not without challenges. Patients often experience significant side effects, including fatigue, nausea, neuropathy, and an increased risk of secondary malignancies. These adverse effects can impact the patient's quality of life and lead to therapy discontinuation. Therefore, a careful risk-benefit assessment is crucial before initiating adjuvant treatment [4].

Emerging trends in adjuvant therapy are focused on precision medicine and personalized approaches. Advances in molecular profiling and next-generation sequencing have enabled oncologists to identify specific molecular targets and tailor therapies accordingly. For instance, the use of PD-1/PD-L1 inhibitors in adjuvant immunotherapy has shown promising results in preventing recurrence in melanoma and lung cancer [5].

In addition to pharmacological interventions, adjuvant radiotherapy plays a critical role in certain cancers, particularly in preventing local recurrence. For example, adjuvant radiotherapy is standard practice in breast-conserving surgery to reduce the risk of local tumor recurrence. Similarly, in rectal cancer, preoperative and adjuvant radiotherapy have demonstrated improved outcomes [6].

The duration and timing of adjuvant therapy are also essential considerations. Evidence suggests that timely initiation of adjuvant therapy—typically within six to eight weeks after surgery—maximizes its efficacy [7].

However, the optimal duration varies depending on the type of cancer and the specific therapeutic regimen.Patient education and shared decision-making are integral to successful adjuvant therapy [8].

Oncologists and healthcare teams must provide clear information about the potential benefits, risks, and expected outcomes of adjuvant treatment. Psychological support and symptom management are also essential to help patients cope with treatment-related challenges [9].

Clinical trials continue to refine the role of adjuvant therapy across different cancer types. Ongoing research aims to identify novel agents, optimize dosing schedules, and minimize adverse effects. For example, trials exploring the combination of adjuvant targeted therapies with immunotherapy are showing potential in improving long-term outcomes [10].

Conclusion

In conclusion, adjuvant therapy remains a vital component of cancer treatment, offering significant benefits in terms of survival and recurrence prevention. However, its success relies on careful patient selection, personalized approaches, and ongoing advancements in oncology research. As precision medicine continues to evolve, the role of adjuvant therapy will likely become even more tailored and effective in the fight against cancer.

References

  1. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324(11):709-15.

    2. Indexed at, Google Scholar, Cross Ref

  2. Abulafi AM, Williams NS. Local recurrence of colorectal cancer: The problem, mechanisms, management and adjuvant therapy. Br J Surg. 1994;81(1):7-19.

    3. Indexed at, Google Scholar, Cross Ref

  3. Goldhirsch A, Gelber RD, Simes RJ, et al. Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis. J Clin Oncol. 1989;7(1):36-44.

    4. Indexed at, Google Scholar, Cross Ref

  4. Imkampe AK, Bates T. Improvements in breast cancer survival over time, related to adjuvant treatment and node status. Eur J Surg Oncol. 2009;35(2):151-5.

    5. Indexed at, Google Scholar, Cross Ref

  5. Brewster AM, Hortobagyi GN, Broglio KR, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008;100(16):1179-83.

    6. Indexed at, Google Scholar, Cross Ref

  6. Pahlman LA, Hohenberger WM, Matzel K, et al. Should the benefit of adjuvant chemotherapy in colon cancer be re-evaluated?. J Clin Oncol. 2016;34(12):1297-9.

    7. Indexed at, Google Scholar, Cross Ref

  7. Makubate B, Donnan PT, Dewar JA, et al. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 2013;108(7):1515-24.

    8. Indexed at, Google Scholar, Cross Ref

  8. Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011;103(11):863-75.

    9. Indexed at, Google Scholar, Cross Ref

  9. Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011;365(15):1396-405.

    10. Indexed at, Google Scholar, Cross Ref

  10. Van de Steene J, Soete G, Storme G. Adjuvant radiotherapy for breast cancer significantly improves overall survival: The missing link. Radiat Oncol. 2000;55(3):263-72.

    11. Indexed at, Google Scholar, Cross Ref

Get the App